Related Experiment Video

Updated: Jul 5, 2026

Intraductal Delivery to the Rabbit Mammary Gland
06:30

Intraductal Delivery to the Rabbit Mammary Gland

Published on: March 9, 2017

Prostaglandin therapy for ductal patency: how long is too long?

Malcolm Brodlie1, Milind Chaudhari, Asif Hasan

  • 1Department of Paediatric Cardiology, Freeman Hospital, Newcastle upon Tyne, United Kingdom.

Acta Paediatrica (Oslo, Norway : 1992)
|May 22, 2008
PubMed

Insights

Managing premature infants with duct-dependent congenital heart defects is difficult. Prolonged prostaglandin infusion successfully delayed cardiac surgery, allowing growth and reducing surgical risks.

Area of Science:

  • Neonatal cardiology
  • Pediatric cardiac surgery
  • Congenital heart disease management

Background:

  • Duct-dependent congenital heart defects (CCHDs) in premature or low birth weight neonates present significant management challenges.
  • Early surgical intervention in these vulnerable infants carries high risks due to prematurity and underdeveloped physiology.

Observation:

  • Two cases of preterm, low birth weight infants with CCHDs are presented.
  • Cardiac surgery was successfully deferred in both cases through medical management.

Findings:

  • Maintaining ductal patency with a prolonged prostaglandin infusion enabled delayed surgical intervention.
  • This approach facilitated infant growth and maturation prior to cardiopulmonary bypass.

Implications:

  • Prolonged prostaglandin infusion is a viable strategy for managing select neonates with CCHDs.
  • Delaying surgery allows for improved patient condition, potentially reducing perioperative morbidity and mortality.
Abstract

More Related Videos

Laparoscopic Oocyte Retrieval and Cryopreservation during Vaginoplasty for Treatment of Mayer-Rokitansky-Kuster-Hauser Syndrome11:53

Laparoscopic Oocyte Retrieval and Cryopreservation during Vaginoplasty for Treatment of Mayer-Rokitansky-Kuster-Hauser Syndrome

Published on: May 10, 2022

Related Concept Videos

Intrauterine Drug Delivery Systems01:21

Intrauterine Drug Delivery Systems

Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Proliferative Phase01:20

Proliferative Phase

The proliferative phase typically occurs after menstruation and lasts between 6 to 13 days in a standard 28-day cycle. This phase involves the reconstruction of the endometrium, guided by estrogen produced by the developing ovarian follicle.
Notably, the stratum basale, the basal layer of the endometrium, including the basal parts of the uterine glands, remains unaffected by menstruation. Stem cells in this layer undergo mitosis, regenerating the stratum functionalis and thickening the...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Birth Control Methods01:22

Birth Control Methods

Vasectomy is a surgical form of male sterilization that involves severing and sealing the vasa deferentia, preventing sperm from mixing with semen during ejaculation. Because a vasectomy does not impact the testes' ability to produce testosterone, hormone levels, libido, and sexual function generally remain unchanged. While vasectomy is highly effective in preventing pregnancy, with a success rate near 99.85%, rare cases of recanalization (spontaneous reconnection) can occur. Although vasectomy...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...